Mesalazine also known as mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
The global market for Mesalazine is estimated to increase from US$ 158.3 million in 2021 to reach US$ 206 million by 2028, exhibiting a CAGR of 3.8% during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Global key players of Mesalazine are Syntese A/S, PharmaZell and Cambrex Corporation etc. The top 3 companies hold a share over 50%. The global Mesalazine are mainly produced in Europe and United States, they occupied for a share over 60%. Europe is the largest market, has a share about 43%, followed by Asia Pacific and North America, with share 31% and 12%, separately.
Report Coverage
This latest report provides a deep insight into the global Mesalazine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Mesalazine market, with both quantitative and qualitative data, to help readers understand how the Mesalazine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Tons.
Market Segmentation:
The study segments the Mesalazine market and forecasts the market size by Purity (Above 97 %, Above 98 % and Above 99 %), by Application (Tablets, Capsules, Pellet and Granule and Suppository), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by purity
Above 97 %
Above 98 %
Above 99 %
Segmentation by application
Tablets
Capsules
Pellet and Granule
Suppository
Enema
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
PharmaZell
Syntese A/S
Cambrex Corporation
Divis Laboratories
Chemi SpA
Ipca Laboratories
Hangzhou Brother
Lianyungang Fengheng Biopharm
Lasa Loboratory
Corden Pharma Bergamo
Erregierre SpA
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical
Chapter Introduction
Chapter 1: Scope of Mesalazine, Research Methodology, etc.
Chapter 2: Executive Summary, global Mesalazine market size (sales and revenue) and CAGR, Mesalazine market size by region, by purity, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Mesalazine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Mesalazine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by purity, and purity.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Mesalazine market size forecast by region, by country, by purity, and application.
Chapter 13: Comprehensive company profiles of the leading players, including PharmaZell, Syntese A/S, Cambrex Corporation, Divis Laboratories, Chemi SpA, Ipca Laboratories, Hangzhou Brother, Lianyungang Fengheng Biopharm and Lasa Loboratory, etc.
Chapter 14: Research Findings and Conclusion